Dogs share our homes, our habits and sometimes, our diseases. Gastric cancer is rare in dogs, but when it does strike, it ...

Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and Bladder. Dr. Brendan Raizenne presented Poster 4578: Prognostic utility ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Rana McKay discussing the molecular and clinical characterization of KLK2 mRNA expression in ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

The vaccine is being used on dogs with three types of cancer — osteosarcoma, hemangiosarcoma, and urothelial carcinoma, a form of bladder cancer. Cancer is the top cause of death for dogs.

Bladder cancer is when a tumor grows in your bladder, a pouch-like organ that stores your urine. (Photo Credit: SEBASTIAN KAULITZKI/Science Source) The American Cancer Society’s estimates for ...

For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving ... Surveillance cystoscopy, imaging and urine cytology occurred after CRT every three to four months. During the ...

Urine samples were collected before cystoscopy and analyzed for PENK methylation, NMP22, and cytology. Pathological confirmation of bladder cancer was conducted by an independent pathologist ...

Not the dog waiting for him for weeks," one user wrote. Another said: "Dogs know. They always know." "The other pup knows," agreed another viewer. "They can smell the cancer." Research suggests ...

A urinary DNA methylation test displayed superior sensitivity for detecting high-grade or invasive bladder cancer, compared with the nuclear matrix protein 22 (NMP22) test or urine cytology test.

Secondary outcomes involved accuracy for overall bladder cancer detection and comparisons with NMP22 and urine cytology tests. Overall, 219 participants had bladder cancer, including 176 with high ...

Fetch’s predictive power to improve pet patient outcomes was recently demonstrated through FidoCure's newly secured patent, a novel targeted therapy and biomarker for canine bladder cancer.